Humana Inc. (NYSE:HUM) Shares Sold by Journey Advisory Group LLC

Journey Advisory Group LLC reduced its stake in shares of Humana Inc. (NYSE:HUM) by 29.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 838 shares of the insurance provider’s stock after selling 357 shares during the period. Journey Advisory Group LLC’s holdings in Humana were worth $313,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in HUM. CarsonAllaria Wealth Management Ltd. increased its stake in shares of Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after acquiring an additional 39 shares during the last quarter. Private Wealth Management Group LLC acquired a new position in Humana in the 4th quarter valued at $32,000. Hantz Financial Services Inc. acquired a new stake in shares of Humana in the 2nd quarter worth $35,000. Family Firm Inc. purchased a new stake in shares of Humana in the second quarter valued at about $37,000. Finally, Riverview Trust Co acquired a new position in shares of Humana during the second quarter worth about $44,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Price Performance

HUM stock opened at $364.81 on Friday. The stock’s 50 day moving average is $367.99 and its two-hundred day moving average is $347.34. Humana Inc. has a 52-week low of $298.61 and a 52-week high of $530.54. The company has a market capitalization of $43.96 billion, a PE ratio of 22.72, a P/E/G ratio of 3.16 and a beta of 0.51. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.70.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.89 by $1.07. The business had revenue of $29.54 billion during the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The business’s revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $8.94 earnings per share. Analysts predict that Humana Inc. will post 16.14 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a yield of 0.97%. Humana’s dividend payout ratio (DPR) is 22.04%.

Analysts Set New Price Targets

A number of brokerages recently commented on HUM. Piper Sandler began coverage on shares of Humana in a research report on Wednesday, June 26th. They issued an “overweight” rating and a $392.00 price objective for the company. TD Cowen lifted their target price on shares of Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Oppenheimer increased their price target on shares of Humana from $370.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. Baird R W upgraded Humana to a “hold” rating in a research report on Thursday, May 30th. Finally, Bank of America increased their target price on Humana from $342.00 to $376.00 and gave the company a “neutral” rating in a report on Monday, May 20th. Thirteen analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $398.70.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.